

Cell Therapy Technologies Market based on By Therapy Type (Autologous, Allogenic), By Therapeutic Area (Oncology, CVD, Dermatology), By Region - Global Forecast up to 2030

<https://marketpublishers.com/r/C89A124957A5EN.html>

Date: January 2024

Pages: 201

Price: US\$ 4,500.00 (Single User License)

ID: C89A124957A5EN

Abstracts

Cell therapy is important in giving diagnostic and prognostic information for a variety of disorders, including HIV/AIDS, cancer, and infectious diseases. It helps academics and healthcare practitioners to acquire insights into disease causes, illness development, and therapy responses using novel cellular-based techniques. Global population expansion, climate change, and greater human-animal interaction have produced an environment conducive to the genesis of novel viral epidemics. Cell therapy research and applications are critical in tackling these issues because they provide enhanced diagnostic tools, therapeutic approaches, and a better knowledge of disease causes.

Cell biology research is primarily concerned with the development of novel medicines such as stem cell and gene therapies. High-quality tools, reagents, and associated goods are required for reliable findings. Meeting regulatory rules and maintaining demanding quality standards in cell biology research, on the other hand, comes at a considerable expense. This is a problem for institutes and small businesses with limited funds, as they may be unable to acquire pricey research products.

Precision medicine is a developing approach to illness treatment and prevention that takes into account genetic, environmental, and lifestyle factors. It entails selecting drugs for each patient depending on their individual condition and medical history. Oncology has made significant advances in precision medicine, even as its use expands to diverse disorders. This personalised approach to diagnosis, treatment, and prevention makes better judgements by utilising full patient information such as genetics, environment, and lifestyle.

The segmentation coverage of the study is provided below.

Cell Therapy Technologies Market based on Therapy Type

Allogeneic Therapies

Stem Cell Therapies

Hematopoietic Stem Cell Therapies

Mesenchymal Stem Cell Therapies

Non-Stem Cell Therapies

Keratinocytes & Fibroblast-based Therapies

Others

Autologous Therapies

Stem Cell Therapies

BM, Blood, & Umbilical Cord-derived Stem Cells

Adipose derived cells

Others

Non-Stem Cell Therapies

T-Cell Therapies

CAR T Cell Therapy

T Cell Receptor (TCR)-based

Cell Therapy Technologies Market based on Therapeutic Area

Cell Therapy Technologies Market based on By Therapy Type (Autologous, Allogenic), By Therapeutic Area (Oncolo...

Oncology

Cardiovascular Disease (CVD)

Musculoskeletal Disorders

Dermatology

Others

Cell Therapy Technologies Market based on Geography

North America

US

Canada

Europe

Germany

UK

France

Italy

Spain

Rest of Europe (RoE)

Asia Pacific (APAC)

China

Japan

India

Australia

South Korea

Rest of Asia Pacific (RoAPAC)

Latin America (LATAM)

Brazil

Argentina

Rest of South America

Middle East and Africa (MEA)

UAE

Turkey

Saudi Arabia

South Africa

Rest of Middle East & Africa

On the basis of cell type, the stem cell segment led the worldwide cell therapy market in 2019, and this trend is expected to continue during the forecast period, as they are gaining popularity as a result of different government initiatives. The number of stem cell banks is increasing in developing countries, which is fueling the expansion of the cell treatment industry. Furthermore, increased understanding of stem cell preservation has a beneficial impact on the cell treatment market growth. Furthermore, the allogenic treatment segment dominated the market in 2019. This therapy is favourable because it includes the generation of one's own immune stem cells, which can destroy cancer cells that survive treatment with high-dose cytotoxic medicines.

It is divided into two types of therapies: autologous and allogenic. The market is divided by therapeutic areas such as malignancies, musculoskeletal diseases, autoimmune disorders, dermatology, and others. It is divided into two types of end-users: hospitals and clinics and academic and research institutes. The market is divided into four regions: North America (the United States, Canada, and Mexico), Europe (Germany, the United Kingdom, France, Spain, Italy, and the rest of Europe), Asia-Pacific (Japan, China, India, Australia, and the rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and the rest of LAMEA).

The hospitals and clinics category is expected to develop at the fastest CAGR throughout the projection period. The segment's profitable expansion may be linked to an increase in the number of pipeline developments over the last few years. According to CRI, the number of cell therapy treatment projects climbed from 753 in 2018 to 1,011 in 2019.

Due to population growth, a growing geriatric population, and increased awareness among healthcare entities and patients about the potential of these therapies in chronic disease management, Asia-Pacific presents lucrative opportunities for key players operating in the cell therapy market. Furthermore, rising healthcare expenditures and the development of guidelines are projected to drive market expansion in the area.

Kolon Tissue Gene, Inc., Osiris Therapeutics, Inc., JCR Pharmaceuticals Co. Ltd., NuVasive, Inc., Stemedica Cell Technologies, Inc., Cells for Cells, Holostem Therapie Avanzate S.r.l., Mesoblast Ltd., and Medipost Co., Ltd. are among the leading companies operating in the global cell therapy market.

This report illustrates the most vital attributes of the Cell Therapy Technologies Market, which are driving and providing opportunities.

This research gives an in-depth analysis of the Cell Therapy Technologies Market growth on the basis of several segments in the market.

This report presents the predictions of the past and present trends of the Cell Therapy Technologies Market.

This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Cell Therapy Technologies Market.

Contents

1. EXECUTIVE SUMMARY

2. INDUSTRY OUTLOOK

2.1. Industry Overview

2.2. Industry Trends

3. MARKET SNAPSHOT

3.1. Market Definition

3.2. Market Outlook

3.2.1. Porter Five Forces

3.3. Related Markets

4. MARKET CHARACTERISTICS

4.1. Market Overview

4.2. Market Segmentation

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. DRO - Impact Analysis

5. THERAPY TYPE: MARKET SIZE & ANALYSIS

5.1. Overview

5.2. Allogeneic Therapies

5.3. Autologous Therapies

6. THERAPEUTIC AREA: MARKET SIZE & ANALYSIS

6.1. Overview

6.2. Oncology

6.3. Cardiovascular Disease (CVD)

6.4. Musculoskeletal Disorders

6.5. Dermatology

6.6. Others

7. GEOGRAPHY: MARKET SIZE & ANALYSIS

7.1. Overview

7.2. North America (U.S., Mexico, Canada)

7.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe)

7.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC)

7.5. Latin America (Brazil, Argentina)

7.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa)

8. COMPETITIVE LANDSCAPE

8.1. Competitor Comparison Analysis

8.2. Market Developments

8.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships

8.2.2. Product Launches and execution

9. VENDOR PROFILES

9.1. Novartis AG

9.1.1. Overview

9.1.2. Financial Overview

9.1.3. Product Offerings

9.1.4. Developments

9.1.5. Business Strategy

9.2. Gilead Sciences, Inc.

9.2.1. Overview

9.2.2. Financial Overview

9.2.3. Product Offerings

9.2.4. Developments

9.2.5. Business Strategy

9.3. Bristol-Myers Squibb Company

9.3.1. Overview

9.3.2. Financial Overview

9.3.3. Product Offerings

9.3.4. Developments

9.3.5. Business Strategy

- 9.4. Johnson & Johnson Services, Inc
 - 9.4.1. Overview
 - 9.4.2. Financial Overview
 - 9.4.3. Product Offerings
 - 9.4.4. Developments
 - 9.4.5. Business Strategy
- 9.5. JCR Pharmaceuticals Co., Ltd.
 - 9.5.1. Overview
 - 9.5.2. Financial Overview
 - 9.5.3. Product Offerings
 - 9.5.4. Developments
 - 9.5.5. Business Strategy
- 9.6. Tego Science
 - 9.6.1. Overview
 - 9.6.2. Financial Overview
 - 9.6.3. Product Offerings
 - 9.6.4. Developments
 - 9.6.5. Business Strategy
- 9.7. Atara Biotherapeutics
 - 9.7.1. Overview
 - 9.7.2. Financial Overview
 - 9.7.3. Product Offerings
 - 9.7.4. Developments
 - 9.7.5. Business Strategy
- 9.8. Takeda Pharmaceutical Company Limited
 - 9.8.1. Overview
 - 9.8.2. Financial Overview
 - 9.8.3. Product Offerings
 - 9.8.4. Developments
 - 9.8.5. Business Strategy
- 9.9. Bluebird Bio, Inc.
 - 9.9.1. Overview
 - 9.9.2. Financial Overview
 - 9.9.3. Product Offerings
 - 9.9.4. Developments
 - 9.9.5. Business Strategy
- 9.10. Dendreon Corp.
 - 9.10.1. Overview
 - 9.10.2. Financial Overview

- 9.10.3. Product Offerings
- 9.10.4. Developments
- 9.10.5. Business Strategy

10. ANALYST OPINION

11. ANNEXURE

- 11.1. Report Scope
- 11.2. Market Definitions
- 11.3. Research Methodology
 - 11.3.1. Data Collation and In-house Estimation
 - 11.3.2. Market Triangulation
 - 11.3.3. Forecasting
- 11.4. Report Assumptions
- 11.5. Declarations
- 11.6. Stakeholders
- 11.7. Abbreviations

Tables

TABLE 1. CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

TABLE 2. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR ALLOGENEIC THERAPIES, BY GEOGRAPHY, 2021-2030 (USD BILLION)

TABLE 3. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR AUTOLOGOUS THERAPIES, BY GEOGRAPHY, 2021-2030 (USD BILLION)

TABLE 4. CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

TABLE 5. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR ONCOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION)

TABLE 6. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR CARDIOVASCULAR DISEASE (CVD), BY GEOGRAPHY, 2021-2030 (USD BILLION)

TABLE 7. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR MUSCULOSKELETAL DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)

TABLE 8. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR DERMATOLOGY, 2021-2030 (USD BILLION)

TABLE 9. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)

TABLE 10. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)

TABLE 11. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

TABLE 12. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

TABLE 13. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

TABLE 14. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

TABLE 15. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

TABLE 16. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

TABLE 17. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

TABLE 18. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

TABLE 19. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

TABLE 20. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

TABLE 21. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

TABLE 22. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

TABLE 23. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)

TABLE 24. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

TABLE 25. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

TABLE 26. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

TABLE 27. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

TABLE 28. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

TABLE 29. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

TABLE 30. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY

TYPE, 2021-2030 (USD BILLION)

TABLE 31. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY
THERAPEUTIC AREA, 2021-2030 (USD BILLION)

TABLE 32. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION,
2021-2030 (USD BILLION)

TABLE 33. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY
THERAPY TYPE, 2021-2030 (USD BILLION)

TABLE 34. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY
THERAPEUTIC AREA, 2021-2030 (USD BILLION)

TABLE 35. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY
REGION, 2021-2030 (USD BILLION)

TABLE 36. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY
TYPE, 2021-2030 (USD BILLION)

TABLE 37. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY
THERAPEUTIC AREA, 2021-2030 (USD BILLION)

TABLE 38. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION,
2021-2030 (USD BILLION)

TABLE 39. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY
THERAPY TYPE, 2021-2030 (USD BILLION)

TABLE 40. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY
THERAPEUTIC AREA, 2021-2030 (USD BILLION)

TABLE 41. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION,
2021-2030 (USD BILLION)

TABLE 42. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY
TYPE, 2021-2030 (USD BILLION)

TABLE 43. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY
THERAPEUTIC AREA, 2021-2030 (USD BILLION)

TABLE 44. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION,
2021-2030 (USD BILLION)

TABLE 45. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY
COUNTRY, 2021-2030 (USD BILLION)

TABLE 46. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY
THERAPY TYPE, 2021-2030 (USD BILLION)

TABLE 47. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY
THERAPEUTIC AREA, 2021-2030 (USD BILLION)

TABLE 48. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY
REGION, 2021-2030 (USD BILLION)

TABLE 49. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY
THERAPY TYPE, 2021-2030 (USD BILLION)

TABLE 50. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

TABLE 51. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

TABLE 52. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

TABLE 53. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

TABLE 54. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

TABLE 55. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

TABLE 56. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

TABLE 57. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

TABLE 58. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

TABLE 59. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

TABLE 60. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

TABLE 61. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

TABLE 62. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

TABLE 63. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

TABLE 64. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

TABLE 65. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

TABLE 66. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

TABLE 67. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

TABLE 68. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

TABLE 69. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY

REGION, 2021-2030 (USD BILLION)

TABLE 70. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

TABLE 71. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

TABLE 72. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

TABLE 73. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

TABLE 74. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

TABLE 75. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

TABLE 76. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

TABLE 77. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

TABLE 78. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

TABLE 79. REST OF MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

TABLE 80. REST OF MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

TABLE 81. REST OF MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

TABLE 82. NOVARTIS AG: FINANCIALS

TABLE 83. NOVARTIS AG: PRODUCTS & SERVICES

TABLE 84. NOVARTIS AG: RECENT DEVELOPMENTS

TABLE 85. GILEAD SCIENCES, INC.: FINANCIALS

TABLE 86. GILEAD SCIENCES, INC.: PRODUCTS & SERVICES

TABLE 87. GILEAD SCIENCES, INC.: RECENT DEVELOPMENTS

TABLE 88. BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS

TABLE 89. BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS & SERVICES

TABLE 90. BRISTOL-MYERS SQUIBB COMPANY: RECENT DEVELOPMENTS

TABLE 91. JOHNSON & JOHNSON SERVICES, INC: FINANCIALS

TABLE 92. JOHNSON & JOHNSON SERVICES, INC: PRODUCTS & SERVICES

TABLE 93. JOHNSON & JOHNSON SERVICES, INC: RECENT DEVELOPMENTS

TABLE 94. JCR PHARMACEUTICALS CO., LTD.: FINANCIALS

TABLE 95. JCR PHARMACEUTICALS CO., LTD.: PRODUCTS & SERVICES

TABLE 96. JCR PHARMACEUTICALS CO., LTD.: RECENT DEVELOPMENTS

TABLE 97. TEGO SCIENCE: FINANCIALS

TABLE 98. TEGO SCIENCE: PRODUCTS & SERVICES

TABLE 99. TEGO SCIENCE: RECENT DEVELOPMENTS

TABLE 100. ATARA BIOTHERAPEUTICS: FINANCIALS

TABLE 101. ATARA BIOTHERAPEUTICS: PRODUCTS & SERVICES

TABLE 102. ATARA BIOTHERAPEUTICS: DEVELOPMENTS

TABLE 103. TAKEDA PHARMACEUTICAL COMPANY LIMITED: FINANCIALS

TABLE 104. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS & SERVICES

TABLE 105. TAKEDA PHARMACEUTICAL COMPANY LIMITED: RECENT DEVELOPMENTS

TABLE 106. BLUEBIRD BIO, INC.: FINANCIALS

TABLE 107. BLUEBIRD BIO, INC.: PRODUCTS & SERVICES

TABLE 108. BLUEBIRD BIO, INC.: RECENT DEVELOPMENTS

TABLE 109. DENDREON CORP.: FINANCIALS

TABLE 110. DENDREON CORP.: PRODUCTS & SERVICES

TABLE 111. DENDREON CORP.: RECENT DEVELOPMENTS

Charts

CHART. 1. CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

CHART. 2. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR ALLOGENEIC THERAPIES, BY GEOGRAPHY, 2021-2030 (USD BILLION)

CHART. 3. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR AUTOLOGOUS THERAPIES, BY GEOGRAPHY, 2021-2030 (USD BILLION)

CHART. 4. CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

CHART. 5. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR ONCOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION)

CHART. 6. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR CARDIOVASCULAR DISEASE (CVD), BY GEOGRAPHY, 2021-2030 (USD BILLION)

CHART. 7. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR MUSCULOSKELETAL DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)

CHART. 8. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR DERMATOLOGY, 2021-2030 (USD BILLION)

CHART. 9. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)

CHART. 10. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)

CHART. 11. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

CHART. 12. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

CHART. 13. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

CHART. 14. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

CHART. 15. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

CHART. 16. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

CHART. 17. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

CHART. 18. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

CHART. 19. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

CHART. 20. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

CHART. 21. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

CHART. 22. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

CHART. 23. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)

CHART. 24. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

CHART. 25. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

CHART. 26. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

CHART. 27. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

CHART. 28. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

CHART. 29. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

CHART. 30. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY

TYPE, 2021-2030 (USD BILLION)

CHART. 31. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

CHART. 32. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

CHART. 33. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

CHART. 34. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

CHART. 35. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

CHART. 36. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

CHART. 37. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

CHART. 38. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

CHART. 39. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

CHART. 40. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

CHART. 41. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

CHART. 42. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

CHART. 43. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

CHART. 44. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

CHART. 45. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)

CHART. 46. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

CHART. 47. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

CHART. 48. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

CHART. 49. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

CHART. 50. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

CHART. 51. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

CHART. 52. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

CHART. 53. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

CHART. 54. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

CHART. 55. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

CHART. 56. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

CHART. 57. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

CHART. 58. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

CHART. 59. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

CHART. 60. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

CHART. 61. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

CHART. 62. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

CHART. 63. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

CHART. 64. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

CHART. 65. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

CHART. 66. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

CHART. 67. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

CHART. 68. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

CHART. 69. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY

REGION, 2021-2030 (USD BILLION)

CHART. 70. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES
MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

CHART. 71. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES
MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)

CHART. 72. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES
MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

CHART. 73. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY
THERAPY TYPE, 2021-2030 (USD BILLION)

CHART. 74. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY
THERAPEUTIC AREA, 2021-2030 (USD BILLION)

CHART. 75. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY
REGION, 2021-2030 (USD BILLION)

CHART. 76. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY
TYPE, 2021-2030 (USD BILLION)

CHART. 77. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY
THERAPEUTIC AREA, 2021-2030 (USD BILLION)

CHART. 78. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION,
2021-2030 (USD BILLION)

CHART. 79. REST OF MIDDLE EAST AND AFRICA CELL THERAPY
TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)

CHART. 80. REST OF MIDDLE EAST AND AFRICA CELL THERAPY
TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD
BILLION)

CHART. 81. REST OF MIDDLE EAST AND AFRICA CELL THERAPY
TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)

CHART. 82. NOVARTIS AG: FINANCIALS

CHART. 83. NOVARTIS AG: PRODUCTS & SERVICES

CHART. 84. NOVARTIS AG: RECENT DEVELOPMENTS

CHART. 85. GILEAD SCIENCES, INC.: FINANCIALS

CHART. 86. GILEAD SCIENCES, INC.: PRODUCTS & SERVICES

CHART. 87. GILEAD SCIENCES, INC.: RECENT DEVELOPMENTS

CHART. 88. BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS

CHART. 89. BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS & SERVICES

CHART. 90. BRISTOL-MYERS SQUIBB COMPANY: RECENT DEVELOPMENTS

CHART. 91. JOHNSON & JOHNSON SERVICES, INC: FINANCIALS

CHART. 92. JOHNSON & JOHNSON SERVICES, INC: PRODUCTS & SERVICES

CHART. 93. JOHNSON & JOHNSON SERVICES, INC: RECENT DEVELOPMENTS

CHART. 94. JCR PHARMACEUTICALS CO., LTD.: FINANCIALS

CHART. 95. JCR PHARMACEUTICALS CO., LTD.: PRODUCTS & SERVICES
CHART. 96. JCR PHARMACEUTICALS CO., LTD.: RECENT DEVELOPMENTS
CHART. 97. TEGO SCIENCE: FINANCIALS
CHART. 98. TEGO SCIENCE: PRODUCTS & SERVICES
CHART. 99. TEGO SCIENCE: RECENT DEVELOPMENTS
CHART. 100. ATARA BIOTHERAPEUTICS: FINANCIALS
CHART. 101. ATARA BIOTHERAPEUTICS: PRODUCTS & SERVICES
CHART. 102. ATARA BIOTHERAPEUTICS: DEVELOPMENTS
CHART. 103. TAKEDA PHARMACEUTICAL COMPANY LIMITED: FINANCIALS
CHART. 104. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS & SERVICES
CHART. 105. TAKEDA PHARMACEUTICAL COMPANY LIMITED: RECENT DEVELOPMENTS
CHART. 106. BLUEBIRD BIO, INC.: FINANCIALS
CHART. 107. BLUEBIRD BIO, INC.: PRODUCTS & SERVICES
CHART. 108. BLUEBIRD BIO, INC.: RECENT DEVELOPMENTS
CHART. 109. DENDREON CORP.: FINANCIALS
CHART. 110. DENDREON CORP.: PRODUCTS & SERVICES
CHART. 111. DENDREON CORP.: RECENT DEVELOPMENTS

I would like to order

Product name: Cell Therapy Technologies Market based on By Therapy Type (Autologous, Allogenic), By Therapeutic Area (Oncology, CVD, Dermatology), By Region - Global Forecast up to 2030

Product link: <https://marketpublishers.com/r/C89A124957A5EN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C89A124957A5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970